Understanding the Drugs and Magic Remedies Act: Protecting Consumers from Misleading Advertisements

Every time you scroll through your phone, you are likely to encounter an advertisement promising a miraculous cure – an herbal concoction that “permanently” eliminates diabetes, a talisman that boosts fertility, or a capsule that guarantees height increase in adults. These claims are not just medically unfounded; in India, they are illegal. The law that governs this space is the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 – a seven-decade-old statute that remains one of the most important consumer protection tools in Indian pharmaceutical and advertising law.

Why this Act was needed 🔗

Before 1954, India had no dedicated law to punish those who published false or exaggerated claims about drug efficacy. The marketplace was flooded with advertisements for alleged cures for serious diseases – cancer, tuberculosis, epilepsy, and venereal diseases – many of which encouraged people to self-medicate instead of consulting a qualified doctor. As the Health Minister noted while introducing the Bill in the Rajya Sabha, these advertisements caused the “ignorant and unwary to resort to self-medication with very harmful drugs,” often leading to serious harm. The primary objective of the Act, as recorded in its preamble, was to prevent self-medication, discourage quackery, and protect public health by banning misleading drug advertisements.

The Act was passed on 30 April 1954 and came into force on 1 April 1955 along with the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955.

Key definitions under the Act 🔗

Three core definitions form the foundation of the Act, and understanding them is essential to grasping its scope.

What is a “drug”? 🔗

The Act defines drug broadly to include any medicine for internal or external use by humans or animals, any substance intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and any article (other than food) that may affect the structure or organic function of the body. This wide definition ensures that the Act captures not just branded pharmaceuticals but also herbal products, tonics, and similar preparations.

What is a “magic remedy”? 🔗

A magic remedy includes any talisman, mantra, kavacha (amulet), or any other charm – whether physical or spoken – that is alleged to have miraculous powers to diagnose, cure, prevent, or mitigate disease in humans or animals. The definition also covers devices claimed to influence the structure or function of any organ. This covers a surprisingly wide range of products, from roadside horoscope remedies to branded “wellness” products making supernatural claims.

What counts as an “advertisement”? 🔗

The Act defines advertisement to include any notice, circular, label, wrapper, or other document – whether written or printed – and any announcement made orally or through light, sound, or smoke. This broad definition was designed to cover all forms of promotion then in use, though it has faced criticism for not explicitly addressing digital and internet-based advertising, a gap the proposed 2020 amendments seek to address.

The core prohibitions: Sections 3 to 6 🔗

The heart of the Act lies in Sections 3 to 6, which set out what advertisements are prohibited.

Section 3 – Prohibition of drug advertisements for certain purposes 🔗

Section 3 prohibits any person from participating in the publication of an advertisement about a drug if the advertisement suggests that the drug can be used for:

• Procuring miscarriage or preventing conception in women;
• Maintaining or improving the capacity for sexual pleasure;
• Correcting menstrual disorders; or
• The diagnosis, cure, mitigation, treatment, or prevention of any disease listed in the Schedule to the Act.

The Schedule originally listed 54 serious diseases, including cancer, tuberculosis, diabetes, epilepsy, blindness, deafness, and venereal diseases. The rationale is clear: these are conditions where delayed or improper treatment can be fatal, and where consumer vulnerability to false promises is highest.

Section 4 – Prohibition of misleading drug advertisements 🔗

Section 4 goes further and prohibits any advertisement about a drug that contains a false claim, misleads about the composition or character of the drug, or is otherwise calculated to deceive the consumer. This section targets not just magical claims but any advertisement that distorts the true nature of a product – even one that does not fall under the Schedule of diseases.

Section 5 – Prohibition of magic remedy advertisements 🔗

While Section 3 deals with drug advertisements, Section 5 specifically targets magic remedies. It prohibits anyone engaged in the manufacture, sale, or distribution of a magic remedy from publishing any advertisement that directly or indirectly claims the remedy is effective for any purpose listed under Section 3. This closes a potential loophole – a product marketed as a “charm” or “ritual” rather than a “drug” still cannot claim to cure the listed diseases.

Section 6 – Prohibition on import and export of objectionable advertisements 🔗

Section 6 extends the Act’s reach beyond India’s borders. It prohibits the import into, or export from, India of any document containing an advertisement of the type covered by Sections 3, 4, or 5. Such documents are treated as prohibited goods under the Sea Customs Act, 1878, making cross-border dissemination of such material a customs offence as well.

Who enforces the Act, and how? 🔗

Enforcement is delegated to gazetted officers authorized by State Governments. Under Section 8, these officers have the power to enter and search any premises, vehicle, or vessel where a violation is suspected, and to seize any printed materials or documents containing prohibited advertisements. Notably, offences under this Act are cognisable, meaning police can arrest an offender without requiring prior approval from a court or magistrate. Only a Presidency Magistrate or a First Class Magistrate can try cases under this Act, ensuring that proceedings are handled by experienced judicial authorities.

Section 11 designates these enforcement officers as public servants under Section 21 of the Indian Penal Code, giving them legal protection while performing their duties. Section 12 provides an indemnity clause – no legal action can be taken against a person for anything done in good faith under the Act.

Penalties under Section 7 🔗

The penalties under the original Act are widely criticized as toothless. For a first conviction, the punishment is imprisonment of up to six months, a fine, or both. For subsequent convictions, it can extend to one year of imprisonment, a fine, or both. When a company commits an offence, every director, manager, or officer responsible for the conduct of the business is deemed guilty unless they can prove the offence was committed without their knowledge and that they exercised due diligence to prevent it.

Exemptions under Section 14 🔗

The Act is not a blanket ban on all medical communication. Section 14 carves out important exemptions. The Act does not apply to:

• Signboards displayed by registered medical practitioners on their own premises indicating that treatment for listed diseases is offered there;
• Any bona fide treatise or book dealing with diseases covered by the Act;
• Advertisements sent confidentially to registered medical practitioners, wholesale or retail chemists, or hospitals or laboratories; and
• Advertisements printed or published by or with the prior sanction of the Government.

These exemptions ensure that legitimate scientific and medical communication is not unnecessarily hampered.

The landmark case: Hamdard Dawakhana v. Union of India (AIR 1960 SC 554) 🔗

The constitutional validity of this Act was challenged almost immediately after it came into force. In the landmark case of Hamdard Dawakhana (Wakf) Lal Kuan v. Union of India (AIR 1960 SC 554), a prominent manufacturer of Unani medicines challenged the Act before a five-judge bench of the Supreme Court. The petitioners argued that the restrictions on advertising violated their fundamental rights to freedom of speech and expression under Article 19(1)(a) and the right to carry on trade or business under Article 19(1)(g) of the Constitution.

The Supreme Court made two critical rulings. First, it upheld the core provisions of the Act as reasonable restrictions on commercial speech justified by public health interests under Article 19(6). The Court held that while an advertisement is technically a form of speech, its “true character is reflected by the object for the promotion of which it is employed” – meaning commercial advertising aimed at promoting a business does not enjoy the same constitutional protection as political or social expression. Second, the Court struck down Section 3(d) and parts of Section 16, finding that the power delegated to the Central Government to add diseases to the Schedule was overly broad and lacked sufficient legislative guidelines, making it unconstitutional as excessive delegation.

The Hamdard Dawakhana case remains a foundational precedent in Indian administrative law – both for its analysis of commercial speech and for the principle that delegated legislative power must be exercised within clearly defined limits.

Limitations and the push for reform 🔗

Despite its importance, the Act has significant limitations that have become more pronounced over time. Critics point out that the law is rarely enforced, and that several products making prohibited claims remain freely available. The disease list is outdated – at least 14 of the diseases originally listed are now curable with modern medicine, while diseases like HIV/AIDS were not on the original Schedule at all. The definition of “advertisement” predates the internet era entirely, leaving social media, websites, and video platforms in a regulatory grey zone.

In response to these gaps, the Ministry of Health and Family Welfare proposed a draft amendment in February 2020. The proposed changes are substantial. The list of prohibited disease claims would be expanded from 54 to 78 conditions, adding categories such as skin fairness, baldness prevention, enhancement of sexual performance, obesity, premature ageing, increase in brain capacity, and improvement in height for children and adults. The definition of “advertisement” would be broadened to expressly cover electronic media, internet platforms, and websites. Most significantly, the penalties would be drastically increased – a first offence would attract up to two years’ imprisonment and a fine of up to ₹10 lakh, while repeat offenders could face up to five years’ imprisonment and a fine of up to ₹50 lakh. As of 2025, these amendments remain pending and have not been introduced in Parliament.

The Act in the broader regulatory landscape 🔗

The Drugs and Magic Remedies Act does not operate in isolation. Section 13 of the Act explicitly states that its provisions are in addition to, and not in derogation of, any other law in force. This means it works alongside the Drugs and Cosmetics Act, 1940; the Cable Television Networks Act, 1995 (which contains its own Advertising Code); the Advertising Standards Council of India’s (ASCI) self-regulatory guidelines; and general provisions of the Indian Penal Code relating to cheating and fraud. Together, these form a layered framework for regulating health-related advertising in India – though enforcement coordination across these frameworks remains a persistent challenge.

The Act’s continued relevance was underscored most visibly during the COVID-19 pandemic, when several companies and individuals were pulled up for advertising unverified cures and treatments. These incidents highlighted both the importance of having such a law and the urgent need to modernize and enforce it more effectively.

What do you think? With social media platforms now saturated with advertisements for miracle health products and “guaranteed” cures, do you think the 70-year-old framework of this Act – even with the proposed 2020 amendments – is sufficient to protect Indian consumers, or does the country need an entirely new regulatory architecture for health advertising in the digital age? And considering that enforcement is currently delegated to State Governments, what structural reforms would make implementation more uniform and effective across India?

References

1. https://www.indiacode.nic.in/handle/123456789/1412
2. https://indiankanoon.org/doc/358950/
3. https://lawbhoomi.com/drugs-and-magic-remedies-objectionable-advertisements-act-1954/
4. https://indiankanoon.org/doc/591481/
5. https://en.wikipedia.org/wiki/Drugs_and_Magic_Remedies_(Objectionable_Advertisements)_Act,_1954
6. https://main.mohfw.gov.in/newshighlights/public-notice-regarding-amendment-drugs-and-magic-remedies-objectionable
7. https://www.mondaq.com/india/food-and-drugs-law/937692/draft-drugs-and-magic-remedies-objectionable-advertisements-amendment-bill-2020
8. https://ascionline.in/